<DOC>
	<DOCNO>NCT01834651</DOCNO>
	<brief_summary>This research study do measure clinical benefit associate cabozantinib ( XL184 ) men prostate cancer spread visceral organ ( organ bone lymph node ) long respond initial hormonal ( castration ) therapy . This type prostate cancer call metastatic , castrate-resistant prostate cancer .</brief_summary>
	<brief_title>A Phase II Study Cabozantinib ( XL184 ) Therapy Castrate Resistant Prostate Cancer ( CRPC ) With Visceral Metastases</brief_title>
	<detailed_description>Cabozantinib ( XL184 ) , multi-targeted tyrosine kinase inhibitor , demonstrate powerful clinical phenotype men metastatic castrate resistant prostate cancer ( mCRPC ) chemotherapy . This phenotype consist rapid reduction pain ( present ) improvement bone scan may may accompany decrease serum prostate specific antigen ( PSA ) concentration . In previous study cabozantinib advanced prostate cancer , patient visceral disease exclude . Hence , protocol creates unique opportunity define activity disease population men visceral disease - marker poor prognosis mCRPC . Primary Objectives : - To assess clinical benefit ( complete response + partial response + stable disease ) cabozantinib patient mCRPC visceral metastasis . Secondary Objectives : - To assess impact cabozantinib number live circulate tumor cell ( CTCs ) use NanoVelcro Chips - To test feasibility measure variation gene expression circulate tumor cell ( CTCs ) response therapy . - To determine impact cabozantinib live circulate tumor cell ( CTC ) number pattern gene expression . - To measure impact cabozantinib serum HGF ( hepatocyte growth factor ) VEGF ( vascular endothelial growth factor ) level men metastatic , castration-resistant prostate cancer ( mCRPC ) . - To assess safety tolerability low dos ( i.e . dose 100 mg daily ) cabozantinib mCRPC visceral involvement . - To collect blood , urine , tissue , plasma may use determine germline genetic variation correlate toxicity . - To pilot correlation molecular content circulate tumor cell ( CTCs ) , large oncosomes , tumor tissue .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>KEY INCLUSION CRITERIA mCRPC include visceral disease . Visceral metastatic disease define solid organ infiltration bone lymph node metastasis . KEY EXCLUSION CRITERIA Recent history ( &lt; 6 month ) gastrointestinal hemorrhage require blood transfusion . Tumor involvement intestinal lining treat physician deems risk perforation rapid tumor response .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>metastatic castrate-resistant</keyword>
	<keyword>prostate cancer</keyword>
</DOC>